Response to cabozantinib in renal cell carcinoma with cardiac metastases

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Cardiac metastases are rare in metastatic renal cell carcinoma (mRCC), often diagnosed posthumously.
• Clinical signs like pericardial effusions and heart failure manifest late.
• Standardized treatments for cardiac metastasis are lacking, with limited data on tyrosine kinase inhibitors (TKIs).

Observation:

• A 66-year-old male with mRCC and cardiac metastases was treated with cabozantinib after sunitinib progression.
• This case represents the first report on cabozantinib's efficacy and safety in mRCC patients with cardiac involvement.
• Real-world data suggest cabozantinib carries a modest risk of left ventricular heart failure.

Findings:

• Cabozantinib demonstrated preliminary efficacy and safety in a patient with mRCC and cardiac metastases.
• The drug's specific inhibition of molecular pathways may contribute to its effectiveness.
• The risk of heart failure in mRCC patients with cardiac metastases receiving cabozantinib remains to be fully elucidated.

Implications:

• This study provides the first evidence of cabozantinib's potential in managing cardiac mRCC.
• Further clinical and molecular research is essential to establish cabozantinib's role in this specific patient population.
• Understanding the safety and efficacy profile is crucial for optimizing treatment strategies for mRCC with cardiac involvement.